Clinical Trials Browser

Phase 3 × Lymphoma, B-Cell × Clear all

NCT06742996 2026-05-22

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Phase 3 Recruiting

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04662255 2026-05-15

BRUIN-MCL-321

Phase 3 Active not recruiting

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03570892 2026-05-14

BELINDA

Phase 3 Completed

330 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06230224 2026-05-11

OLYMPIA-4

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Phase 3 Active not recruiting

238 enrolled 17 charts 1 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05254743 2026-04-20

BRUIN-CLL-314

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07516093 2026-04-08

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Phase 3 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07188558 2026-03-04

PiNACLE-H2H

Phase 3 Recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Phase 3 Completed

482 enrolled 1 FDA

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04965493 2026-01-29

BRUIN CLL-322

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05023980 2026-01-22

BRUIN CLL-313

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase 3 Completed

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05431179 2023-04-21

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3 Withdrawn

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02787239 2022-05-09

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Phase 3 Completed

Lymphoma, B-Cell

NCT05164770 2021-12-21

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3 Unknown

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00329030 2021-11-01

BMTCTN0401

Phase 3 Completed

224 enrolled 24 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic

NCT04539119 2020-09-04

Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA

Phase 3 Unknown

Lymphoma, B-Cell

NCT02366663 2018-03-12

SPINOZA

Phase 3 Terminated

3 enrolled 8 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00486759 2017-07-25

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Phase 3 Terminated

787 enrolled 8 charts

Lymphoma, B-Cell

NCT00790036 2017-07-12

PILLAR2

Phase 3 Completed

742 enrolled 10 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT00841945 2017-02-23

Treatment of Aggressive Localized Lymphoma

Phase 3 Terminated

Lymphoma, B-Cell

NCT02777736 2016-06-06

CLSG-CNS-001

Phase 3 Unknown

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00854568 2014-08-20

Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Phase 3 Completed

Lymphoma, Lymphoma, B-Cell, Cardiotoxicity

NCT00312845 2012-06-25

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Phase 3 Completed

676 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00162656 2012-03-28

Treatment of Mature B-cell Lymphoma/Leukaemia

Phase 3 Completed

Lymphoma, B-Cell

NCT00168740 2005-09-15

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Phase 3 Completed

Lymphoma, B-Cell